Cargando…

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

PURPOSE: Acadesine has shown in vitro to selectively induce apoptosis in B cells from chronic lymphocytic leukemia (CLL) patients. We conducted a phase I/II open-label clinical study, to determine the safety and tolerability of acadesine given intravenously as a 4-h infusion to CLL patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Den Neste, Eric, Cazin, Bruno, Janssens, Ann, González-Barca, Eva, Terol, María José, Levy, Vincent, Pérez de Oteyza, Jaime, Zachee, Pierre, Saunders, Andrew, de Frias, Mercè, Campàs, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579463/ https://www.ncbi.nlm.nih.gov/pubmed/23228986 http://dx.doi.org/10.1007/s00280-012-2033-5

Ejemplares similares

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Acadesine Triggers Non-apoptotic Death in Tumor Cells
por: Glazunova, V. A., et al.
Publicado: (2013)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Simon, Florian, et al.
Publicado: (2023)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

How I manage patients with relapsed/refractory diffuse large B cell lymphoma
por: Gisselbrecht, Christian, et al.
Publicado: (2018)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Microvesicles in CLL: predictor of disease progression/relapse
por: Maiti, Guru P., et al.
Publicado: (2017)

Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
por: Robert, Guillaume, et al.
Publicado: (2009)

Synthesis of New Acadesine (AICA-riboside) Analogues Having Acyclic d-ribityl or 4-Hydroxybutyl Chains in Place of the Ribose
por: D’Errico, Stefano, et al.
Publicado: (2013)

Acadesine suppresses TNF-α induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells
por: Efstathiou, Nikolaos E., et al.
Publicado: (2020)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
por: Lin, Guoqiang, et al.
Publicado: (2021)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
por: Agrawal, Rohitashva, et al.
Publicado: (2020)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2023)

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
por: Yildiz, Halil, et al.
Publicado: (2021)

Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
por: Aldapt, Mahmood B, et al.
Publicado: (2021)

Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
por: Molica, Stefano, et al.
Publicado: (2021)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
por: Pei, Kunlin, et al.
Publicado: (2023)

P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
por: Liang, Emily, et al.
Publicado: (2023)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6gq6s5njvvpgd8ukd3ggl7i35i